Implementation of durvalumab maintenance treatment after concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer (NSCLC)-a German radiation oncology survey.

ABSTRACT:

Background

Durvalumab as maintenance treatment after platinum-based concurrent chemoradiotherapy (cCRT) has become the standard of care in inoperable stage III non-small cell lung cancer (NSCLC). In this nationwide survey, we solicited members of the German Radiation Oncology Society to review the current distribution and clinical settings of durvalumab treatment after cCRT, observed side effects and summarize follow-up management.

Methods

We surveyed radiation oncology institutions in Germany via an anonymous online questionnaire sent by e-mail to all members of the German Radiation Oncology Society which agreed their willingness to participate.

Results

We received a total of 255 responses (response rate: 18%). Of which 203 (80%) were completed and returned and thus

SUBMITTER: Kasmann L 

PROVIDER: S-EPMC7225149 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature